147 related articles for article (PubMed ID: 29032238)
21. Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance.
Ha YS; Yu J; Salmasi AH; Patel N; Parihar J; Singer EA; Kim JH; Kwon TG; Kim WJ; Kim IY
Urology; 2014 Aug; 84(2):365-71. PubMed ID: 24925834
[TBL] [Abstract][Full Text] [Related]
22. Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria.
Almeida GL; Petralia G; Ferro M; Ribas CA; Detti S; Jereczek-Fossa BA; Matei DV; Coman I; De Cobelli O; Tagliabue E
Urol Int; 2016; 96(4):459-69. PubMed ID: 27045167
[TBL] [Abstract][Full Text] [Related]
23. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
24. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance.
de Cobelli O; Terracciano D; Tagliabue E; Raimondi S; Galasso G; Cioffi A; Cordima G; Musi G; Damiano R; Cantiello F; Detti S; Victor Matei D; Bottero D; Renne G; Ferro M
Urol Oncol; 2015 May; 33(5):201.e1-8. PubMed ID: 25791753
[TBL] [Abstract][Full Text] [Related]
25. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
Magheli A; Hinz S; Hege C; Stephan C; Jung K; Miller K; Lein M
J Urol; 2010 Jan; 183(1):126-31. PubMed ID: 19913257
[TBL] [Abstract][Full Text] [Related]
26. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
Cooperberg MR; Cowan JE; Lindquist KJ; Kobayashi Y; Simko JP; Bengtsson H; Singh K; Ngo V; Avila A; Newcomb LF; Tretriakova M; Lin DW; Stone S; Carroll PR; Paris PL
Eur Urol; 2021 Jan; 79(1):141-149. PubMed ID: 33148472
[TBL] [Abstract][Full Text] [Related]
27. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
[TBL] [Abstract][Full Text] [Related]
28. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
29. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
30. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
31. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.
Porcaro AB; Gallina S; Bianchi A; Cerrato C; Tafuri A; Rizzetto R; Amigoni N; Orlando R; Serafin E; Gozzo A; Migliorini F; Antoniolli SZ; Lacola V; De Marco V; Brunelli M; Cerruto MA; Siracusano S; Antonelli A
Int Urol Nephrol; 2021 Dec; 53(12):2505-2515. PubMed ID: 34677784
[TBL] [Abstract][Full Text] [Related]
32. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
[TBL] [Abstract][Full Text] [Related]
33. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging.
Bakavicius A; Daniunaite K; Zukauskaite K; Barisiene M; Jarmalaite S; Jankevicius F
Clin Epigenetics; 2019 Aug; 11(1):115. PubMed ID: 31383039
[TBL] [Abstract][Full Text] [Related]
34. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Sorce G; Flammia RS; Hoeh B; Chierigo F; Hohenhorst L; Panunzio A; Stabile A; Gandaglia G; Tian Z; Tilki D; Terrone C; Gallucci M; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Prostate; 2022 Jun; 82(10):1040-1050. PubMed ID: 35365851
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.
Radwan MH; Yan Y; Luly JR; Figenshau RS; Brandes SB; Bhayani SB; Bullock AD; Liefu Y; Andriole GL; Kibel AS
Urology; 2007 Jun; 69(6):1121-7. PubMed ID: 17572199
[TBL] [Abstract][Full Text] [Related]
36. A contemporary analysis of disease upstaging of Gleason 3 + 3 prostate cancer patients after robot-assisted laparoscopic prostatectomy.
Taggart R; Dutto L; Leung HY; Salji M; Ahmad I
Cancer Med; 2023 Nov; 12(22):20830-20837. PubMed ID: 37929881
[TBL] [Abstract][Full Text] [Related]
37. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
38. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.
Aslan G; Irer B; Kefi A; Celebi I; Yörükoğlu K; Esen A
Int Urol Nephrol; 2005; 37(3):511-4. PubMed ID: 16307332
[TBL] [Abstract][Full Text] [Related]
39. PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy.
Hofner T; Pfitzenmaier J; Alrabadi A; Pahernik S; Hadaschik B; Wagener N; Djakovic N; Haferkamp A; Hohenfellner M
World J Urol; 2012 Feb; 30(1):91-5. PubMed ID: 21193912
[TBL] [Abstract][Full Text] [Related]
40. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
